Table 1 The anti-proliferative IC50 values of the Glycosyl heterocyclic scaffolds (2-10b) on the four tested cell lines following LDH assay.

From: New benzimidazole-triazole glycoconjugates as anti-cancer agents and EGFR inhibitors

Compound ID

IC50 (µM) ± SD

HepG-2

MCF-7

HCT-116

BJ-1

2

1.72 ± 0.23

2.48 ± 0.05

6.51 ± 1.33

34.58 ± 2.72

3

3.25 ± 0.31

2.97 ± 0.20

6.85 ± 1.56

95.28 ± 5.44

5a

3.27 ± 0.34

3.79 ± 0.27

6.49 ± 1.18

49.21 ± 3.78

5b

1.65 ± 0.13

2.73 ± 0.12

7.74 ± 1.52

11.22 ± 1.30

6a

1.61 ± 0.25

2.48 ± 0.16

6.49 ± 1.33

9.31 ± 1.43

6b

1.67 ± 0.12

2.98 ± 0.25

9.97 ± 0.98

31.85 ± 2.31

7a

1.68 ± 0.26

2.21 ± 0.18

7.84 ± 0.69

8.69 ± 1.73

7b

1.61 ± 0.13

2.34 ± 0.30

8.20 ± 1.43

9.03 ± 1.59

8a

1.67 ± 0.12

2.89 ± 0.29

8.68 ± 0.91

10.87 ± 1.64

8b

1.55 ± 0.15

2.08 ± 0.11

5.94 ± 0.80

11.78 ± 2.24

9a

1.64 ± 0.11

1.99 ± 0.11

5.00 ± 0.51

14.67 ± 2.32

9b

1.63 ± 0.28

2.06 ± 0.13

5.28 ± 0.50

8.93 ± 1.25

10a

1.72 ± 0.29

2.06 ± 2.04

8.29 ± 1.44

˃ 500

10b

1.62 ± 0.15

3.39 ± 0.22

5.36 ± 0.42

15.79 ± 1.64

Erlotinib

2.07 ± 0.07

1.05 ± 0.03

5.14 ± 0.33

14.5 ± 1.97

Doxorubicin

3.81 ± 0.25

1.81 ± 0.15

8.12 ± 0.65

6.04 ± 0.31

Back to article page